Differences in Assessment of Everyday Preferences Between People With Cognitive Impairment and Their Care Partners: The Role of Neuropsychiatric Symptoms

Mild cognitive impairment (MCI) and dementia are clinically prevalent in the elderly. There is a high risk of cognitive decline in patients diagnosed with MCI or dementia. This review describes the effectiveness of Ginkgo biloba leaf special extract EGb 761® for the treatment of dementia syndromes and EGb 761® combination therapy with other medications for symptomatic dementia. This drug has shown convincing results, improving cognitive function, neuropsychiatric symptoms and consequent reduction of caregiver stress and maintenance of autonomy in patients with age-related cognitive decline, MCI and mild to moderate dementia. Currently, there is little evidence to support the combination therapy with anti-dementia drugs and, therefore, more evidence is needed to evaluate the role of EGb 761® in mixed therapy.

Download Full-text

The Neuroinflammasome in Alzheimer’s Disease and Cerebral Stroke

Dementia and Geriatric Cognitive Disorders Extra ◽

10.1159/000516074 ◽

2021 ◽

pp. 159-167

Author(s):

Jong-hoon Lee ◽

Chul Joong Lee ◽

Jungwuk Park ◽

So Jeong Lee ◽

Su-hee Choi

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Cognitive Impairment ◽

Mild Cognitive Impairment ◽

Neuropsychiatric Symptoms ◽

Clinical Staging ◽

Cerebral Stroke ◽

Study Cohort ◽

Diaminodiphenyl Sulfone

Aim/Background: This review investigated a patient with Alzheimer’s disease (AD) treated with 4,4’-diaminodiphenyl sulfone (DDS) as a neuroinflammasome competitor. Methods: We monitored AD’s progression through numeric clinical staging (NCS) with a new biomarker. NCS was determined by the presence of AD symptoms and neuropsychiatric (NP) symptoms caused by anti-AD (AAD) drugs (D) as a biomarker. We also monitored the function of DDS for stroke in a no-intake emergency state. Results: By introducing (D), AD’s progression was monitored through NCS staging. AAD side effects and neuropsychiatric symptoms were identified. DDS was stopped in patients with stroke with NCS 6 caused by AAD, and it rapidly proceeded to cerebral infarct. Conclusions: AAD can occasionally exacerbate AD and stroke. DDS can alleviate mild cognitive impairment (MCI), early AD and stroke. We clinically confirmed the role of DDS as a neuroinflammasome competitor after stroke. DDS preserved neuronal survival within 24–55 h in the Seoul Study cohort.

Download Full-text

KCNA2 Autoimmunity in Progressive Cognitive Impairment: Case Series and Literature Review

Brain Sciences ◽

10.3390/brainsci11010089 ◽

2021 ◽

Vol 11 (1) ◽

pp. 89

Author(s):

Charles Timäus ◽

Philipp von Gottberg ◽

Sina Hirschel ◽

Claudia Lange ◽

Jens Wiltfang ◽

...

Keyword(s):

Cognitive Impairment ◽

Cognitive Deficits ◽

Cognitive Impairments ◽

Neuropsychiatric Symptoms ◽

Case Series ◽

Causal Link ◽

Current Evidence ◽

Progressive Dementia ◽

Systematic Assessment

Autoimmune dementia is a novel and expanding field which subsumes neuropsychiatric disorders with predominant cognitive impairments due to an underlying autoimmune etiology. Progressive dementias with atypical clinical presentation should trigger a thorough diagnostic approach including testing for neural surface and intracellular antibodies to avoid a delay in accurate diagnosis and initiating appropriate therapy. Here, we present two emerging cases of progressive dementia with co-existing serum autoantibodies against the KCNA2 (potassium voltage-gated channel subfamily A member 2) subunit. We found various cognitive deficits with dominant impairments in the memory domain, particularly in delayed recall. One patient presented a subacute onset of then-persisting cognitive deficits, while the other patient’s cognitive impairments progressed more chronically and fluctuated. Cognitive impairments coincided with additional neuropsychiatric symptoms. Both had a potential paraneoplastic background according to their medical history and diagnostic results. We discuss the potential role of KCNA2 autoantibodies in these patients and in general by reviewing the literature. The pathogenetic role of KCNA2 antibodies in cognitive impairment is not well delineated; clinical presentations are heterogeneous, and thus a causal link between antibodies remains questionable. Current evidence indicates an intracellular rather than extracellular epitope. We strongly suggest additional prospective studies to explore KCNA2 antibodies in specifically-defined cohorts of cognitively impaired patients via a systematic assessment of clinical, neuropsychological, neuroimaging, as well as laboratory and CSF (cerebrospinal fluid) parameters, and antibody studies to (1) determine the epitope’s location (intracellular vs. extracellular), (2) the mode of action, and (3) seek co-existing, novel pathogenetic autoantibodies in sera and CSF.

Download Full-text

P3-307: NEUROPSYCHIATRIC SYMPTOMS AS PREDICTORS OF PROGRESSION IN MILD COGNITIVE IMPAIRMENT (MCI) AND MILD ALZHEIMER'S DISEASE (AD): THE ROLE OF APATHY

Alzheimer s & Dementia ◽

10.1016/j.jalz.2019.06.3339 ◽

2019 ◽

Vol 15 ◽

pp. P1055-P1055

Author(s):

Kristabella Low ◽

Noorhazlina Ali ◽

Mark Chan ◽

Laura Tay ◽

Wee Shiong Lim ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Cognitive Impairment ◽

Mild Cognitive Impairment ◽

Neuropsychiatric Symptoms

Download Full-text

The neuro-inflammasome in Alzheimer’s disease and cerebral stroke

10.31219/osf.io/ed9mb ◽

2021 ◽

Author(s):

Jong-hoon Lee

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Cognitive Impairment ◽

Mild Cognitive Impairment ◽

Side Effects ◽

Neuropsychiatric Symptoms ◽

Clinical Staging ◽

Cerebral Stroke ◽

Diaminodiphenyl Sulfone

Aim/Background: This Review investigated a patient with Alzheimer’s disease (AD) treated with 4,4’-diaminodiphenyl sulfone (DDS) as a neuro-inflammasome competitor.Methods: We monitored AD’s progression through Numeric Clinical staging (NCS) with a new biomarker. NCS was determined by the AD symptoms and neuropsychiatric (NP) symptoms caused by anti-AD drugs (AAD) as a biomarker (D). We also monitored the function of DDS for Stroke in a no-intake emergency state.Results: By introducing (D), AD's progression was monitored through NCS staging; AAD side effects and neuropsychiatric symptoms were distinguished. DDS was stopped in the Stroke with NCS 6 by AAD, and it rapidly proceeds to cerebral infarct.Conclusions: AADs can occasionally exacerbate AD and Stroke. DDS can alleviate mild cognitive impairment (MCI), early AD and Stroke. We clinically confirmed the role of DDS as a neuro-inflammasome competitor after Stroke. DDS keep neuronal survivals within 24 - 55 hours in the Seoul cohort.

Download Full-text

Working towards inclusion: Creating technology for and with people living with mild cognitive impairment or dementia who are employed

Dementia ◽

10.1177/14713012211051885 ◽

2021 ◽

pp. 147130122110518

Author(s):

Karan Shastri ◽

Jennifer Boger ◽

Sheida Marashi ◽

Arlene Astell ◽

Erica Dove ◽

...

Keyword(s):

Cognitive Impairment ◽

Mild Cognitive Impairment ◽

Lessons Learned ◽

Early Onset Dementia ◽

Workplace Experiences ◽

Use Of Technology ◽

People With Dementia ◽

Care Partners ◽

Dementia Research

Earlier diagnosis and longer working careers is resulting in more individuals being identified as having Mild Cognitive Impairment or Early Onset Dementia (MCI/EOD) when they are still in the workforce. While there is growing interest in the dementia research community and beyond to develop technologies to support people with dementia, the use of technology for and by people with MCI/EOD in the workplace has had very little attention. This paper presents a two-part study involving interviews and participatory sessions to begin to understand the workplace experiences and the role of technology among people living with MCI/EOD. We present our findings from working with seven people with MCI/EOD and two care partners to explore technology design. Our results indicate several similarities as well as a few differences between MCI/EOD and later-onset dementia with respect to challenges using technology and design considerations for supporting engagement and use of technology. Lessons learned through the process of working with people with MCI/EOD through participatory methods is presented along with recommendations to foster an inclusive, respectful, and empowering experience for participants with MCI/EOD.

Download Full-text

The neuro-inflammasome in Alzheimer’s disease and cerebral Stroke

10.21203/rs.3.rs-533128/v1 ◽

2021 ◽

Author(s):

JONG HOON LEE ◽

Chul Joong Lee ◽

Jungwuk Park ◽

So Jeong Lee ◽

Su-hee Choi

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Cognitive Impairment ◽

Mild Cognitive Impairment ◽

Side Effects ◽

Neuropsychiatric Symptoms ◽

Clinical Staging ◽

Cerebral Stroke ◽

Diaminodiphenyl Sulfone

Abstract Aim/Background: This Review investigated a patient with Alzheimer’s disease (AD) treated with 4,4’-diaminodiphenyl sulfone (DDS) as a neuro-inflammasome competitor.Methods: We monitored AD’s progression through Numeric Clinical staging (NCS) with a new biomarker. NCS was determined by the AD symptoms and neuropsychiatric (NP) symptoms caused by anti-AD drugs (AAD) as a biomarker (D). We also monitored the function of DDS for Stroke in a no-intake emergency state.Results: By introducing (D), AD's progression was monitored through NCS staging; AAD side effects and neuropsychiatric symptoms were distinguished. DDS was stopped in the Stroke with NCS 6 by AAD, and it rapidly proceeds to cerebral infarct.Conclusions: AADs can occasionally exacerbate AD and Stroke. DDS can alleviate mild cognitive impairment (MCI), early AD and Stroke. We clinically confirmed the role of DDS as a neuro-inflammasome competitor after Stroke. DDS keep neuronal survivals within 24 - 55 hours in the Seoul cohort.

Download Full-text